Jazz Pharmaceuticals has delivered a strong multi year share price run alongside high profile product and pipeline news, which naturally raises the question of whether its current valuation is still grounded in the earnings backing the business. With Jazz now firmly in the spotlight after recent oncology and rare disease updates, the key issue for you is how much of that story is already reflected in the price.
-
Over the past 3 years the stock has returned 61.5%, putting real weight on the question of whether today's earnings can support that step up in market value.
-
Record recent revenues, the launch of Ziihera in HER2 positive gastroesophageal cancer and the Actio Biosciences acquisition all feed into expectations for future profit streams that may support a different earnings profile than in the past.
-
There is a second opinion on Jazz Pharmaceuticals worth weighing. See
The issue now is whether Jazz Pharmaceuticals' current share price is justified by the earnings that investors can reasonably tie to the business today.
If you want to test the same earnings based valuation question across a wider set of companies, take a look at 34 high quality undervalued stocks.
Does Jazz...